ENO1 and neoplasm: Sun and colleagues first established the ENO1-YAP1/PLCB1/HPGD regulatory axis, demonstrating its glycolytic-independent mechanism in promoting tumor growth via arachidonic acid (AA) metabolic reprogramming.